Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 6/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzenesulfonamide SCHEMBL16238901 | 0.89 | CA1 (0.56) | LIPEHTTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL16239255 | 0.88 | TNF (0.55) | LIPEHTTKDM4EALDH1A1MAPT | |
| SCHEMBL14907137 | 0.88 | LIPE (0.55) | LIPEHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14907228 | 0.88 | LIPE (0.66) | LIPESMN1; SMN2KDM4EALDH1A1PRMT5 | |
| SCHEMBL16238884 | 0.86 | LIPE (0.51) | LIPEMAPT | |
| SCHEMBL7479368 | 0.85 | LIPE (0.68) | LIPEHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16239253 | 0.84 | NPC1 (0.55) | LIPEHTTSMN1; SMN2KDM4EMAPT | |
| SCHEMBL14890633 | 0.84 | LIPE (0.73) | LIPESMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL16251376 | 0.82 | LIPE (0.50) | LIPEHTTSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL16251377 | 0.80 | TRPV1 (0.51) | LIPESMN1; SMN2KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546426-B2 | N-aminotetrahydroisoquinolines as anti-cancer agents | Florida A&M University Board of Trustees (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546426-B2 | N-aminotetrahydroisoquinolines as anti-cancer agents | Florida A&M University Board of Trustees (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130109716-A1 | N-AMINOTETRAHYDROISOQUINOLINES AS ANTI-CANCER AGENTS | Florida A&M University Board of Trustees (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109716-A1 | N-AMINOTETRAHYDROISOQUINOLINES AS ANTI-CANCER AGENTS | Florida A&M University Board of Trustees (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109716-A1 | N-AMINOTETRAHYDROISOQUINOLINES AS ANTI-CANCER AGENTS | TNS4, BRCA1, MKI67 | LIPE 4473/4885HTT 2783/4885SMN1; SMN2 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.